Structured evidence table for Probiotic Skin Acne Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Probiotic Skin Acne Randomized Trial | Standard therapy often relies on antibiotics, but the long-term use has increased antibiotic resistance, including in Indonesia. | 2 | Lestari K (2026) | Oral probiotics and topical secretome to enhance clinical outcomes and microbiome restoration in acne vulgaris: a double-blind, randomised controlled trial protocol. |
| Probiotic Skin Acne Randomized Trial | Background Acne vulgaris is a chronic inflammatory condition primarily caused by Cutibacterium acnes , which disrupts skin homeostasis, thereby triggering immune responses and sebum metabolism. | 2 | Lestari K (2026) | Oral probiotics and topical secretome to enhance clinical outcomes and microbiome restoration in acne vulgaris: a double-blind, randomised controlled trial protocol. |
| Probiotic Skin Acne Randomized Trial | Dysbiosis is an imbalance in the skin and gut microbiota identified as a significant factor contributing to acne progression. | 2 | Lestari K (2026) | Oral probiotics and topical secretome to enhance clinical outcomes and microbiome restoration in acne vulgaris: a double-blind, randomised controlled trial protocol. |
| Probiotic Skin Acne Randomized Trial | Acne vulgaris is a chronic inflammatory condition with multifactorial pathogenesis. | 4 | Burckhardt-Bravo V (2026) | Update on novel acne treatments: a narrative review focused on microbiome modulation and non-pharmacological approaches. |
| Probiotic Skin Acne Randomized Trial | Despite the availability of numerous treatment options, there remains a need for safe, well-tolerated, and microbiome-preserving therapies. | 4 | Burckhardt-Bravo V (2026) | Update on novel acne treatments: a narrative review focused on microbiome modulation and non-pharmacological approaches. |
Source documents